Vol. 3 No. 5

Review Articles

Metabonomics and it’s Potential Application in Clinic Diagnosis and Therapy

Published 2026-09-30

  • Chunlei Xie
    • ,
  • Congcong Tang
    • ,
  • Qi Tang
    • ,
  • Faqing Tang

Chunlei Xie


Congcong Tang
Hunan Cancer Hospital image/svg+xml

Qi Tang
Hunan Cancer Hospital image/svg+xml

Faqing Tang
Hunan Cancer Hospital image/svg+xml

Abstract

Metabolomics is a new-generation omics technology emerging after genomics, transcriptomics, and proteomics, It focuses on all small-molecule metabolites with molecular weights below 1 kDa within biological systems, providing a direct reflection of the terminal phenotypic changes in the physiological and pathological states of organisms. With the continuous iteration of detection platforms such as mass spectrometry and nuclear magnetic resonance, both untargeted and targeted metabolomics have been widely used to screen disease-specific metabolic biomarkers and construct non-invasive, and precise disease diagnostic models. This article summarized the main technical platforms and data analysis workflows of metabolomics, consolidated diagnostic applications of metabolomics in the fields including malignant tumors, metabolic diseases, neurological disorders, and autoimmune diseases, while discussing current bottlenecks in sample standardization, biomarker validation, and metabolic-disease causal analysis. Additionally, the article also explored the development prospects of artificial intelligence combined with spatial metabolomics in clinical precision diagnostics, it provides a reference for the translation of metabolomics from basic research to clinical diagnosis.

Keywords

Metabolomics, Biomarkers, Mass spectrometry, Disease diagnosis, Precision medicine, Non-invasive testing

PDF

References

  1. Zhang N, Dong N, Xie AR, et al. Urinary extracellular vesicle metabolomic profiling reveals a distinct molecular signature for the non-invasive diagnosis of lupus nephritis. Front. Immunol. 2026; 17.
  2. You J, Cui XH, Chen YL, et al. Mapping the plasma metabolome to human health and disease in 274,241 adults. Nat Metab. 2025;7(11):2366-2384.
  3. Qiang YX, Wang YX, He XY, et al. Genetic architecture of plasma metabolome in 254,825 individuals. Nat Commun. 2025;16(1):8272.
  4. He SY, Zeng HD, Li BY. Application Progress of Spatially Resolved Metabolomics in Disease Diagnosis Research. Biotechnology Bulletin. 2024; 40 (1): 145-159.
  5. Nicholson JK, Lindon JC , Holmes E. Metabonomics : understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotic.1999;29(1):1812-1189.
  6. Liu X, Locasale J W. Metabolomics: A primer. Trends in Biochemical Sciences. 2017;42(4): 274‑284.
  7. Warwick BD, David IE. Metabolomics: Current analytical platforms and methodologies. Trends in Analytical Chemistry. 2000;24(4):285-294.
  8. Chen YZ, Wang BH, Zhao YZ, et al. Metabolomic machine learning predictor for diagnosis and prognosis of gastric cancer. Nat Commun. 2024;15(1):1657.
  9. Patra S, Dutta D, Calra S, et al. Metabolomics in Endocrinology: The Way Forward. Indian J Endocrinol Metab. 2025;29(4):394–401
  10. Patti G J, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nature Reviews Molecular Cell Biology. 2012;13(4):263‑269.
  11. Crook AA, Powers R. Quantitative NMR-Based Biomedical Metabolomics: Current Status and Applications. Molecules. 2020;25(21):5128.
  12. Xu H,Lin HD, Liu CX.Current Status and Prospects of Metabolomics Research. Acta Pharmaceutica Sinica.2005;40(9):769 -774.
  13. Huang Q, Shen X, Li Y, Wu H, et al .A Metabolomics-Driven Integrated Machine Learning Framework for Early Prediction of Recurrent Acute Pancreatitis. Metabolites. 2026;16(8):575.
  14. Chen F, Yeung PS, Wong CV, et al. High-resolution mass spectrometry measurement of N-terminal carbamylated hemoglobin as a potential marker for chronic diseases with elevated blood urea levels. J Mass Spectrom Adv Clin Lab. 2025;35:8-13.
  15. Panighel A, Flamini R. Applications of solid-phase microextraction and gas chromatography/mass spectrometry (SPME-GC/MS) in the study of grape and wine volatile compounds. Molecules. 2014;19(12):21291-309.
  16. Ngai YT, Lau D, Mittal P, et al. Mini Review: Highlight of Recent Advances and Applications of MALDI Mass Spectrometry Imaging in 2024. Anal Sci Adv. 2025;6(1):e70016.
  17. Ma S, Dai Y. Principal component analysis based methods in bioinformatics studies. Brief Bioinform. 2011;12(6):714-22.
  18. Worley B, Powers R. PCA as a practical indicator of OPLS-DA model reliability. Curr Metabolomics. Author manuscript. 2016;4(2):97-103.
  19. An Q, Rahman S, Zhou J, et al. A Comprehensive Review on Machine Learning in Healthcare Industry: Classification, Restrictions, Opportunities and Challenges. Sensors (Basel). 2023;23(9):4178.
  20. Rakusanova S, Cajka T. Metabolomics and Lipidomics for Studying Metabolic Syndrome: Insights into Cardiovascular Diseases, Type 1 & 2 Diabetes, and Metabolic Dysfunction-Associated Steatotic Liver Disease. Physiol Res. 2024; 73(S1):S165-S183.
  21. Yan XZ. Metabolomics technology and its application in the discovery of clinical disease biomarkers.Journal of Analytical Testing.2021;40(05):641‑648.
  22. Xu Z, Zhou Y, Xie R, et al. Metabolomics uncovers the diabetes metabolic network: from pathophysiological mechanisms to clinical applications. Front Endocrinol (Lausanne). 2025;16:1624878.
  23. Yang J, Xu GW, Hong QF, et al. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profile. Journal of Chromatography B. 2004;813:53-58.
  24. Wang C, Kong HW, Yang J, et al. Plasma Phospholipid Metabolic Profiling and Biomarkers of Type 2 Diabetes Mellitus Based on High-Performance Liquid Chromatography/Electrospray Mass Spectrometry and Multivariate Statistical Analysis.Anal.Chem.2005;77:4108-4110.
  25. Michael SH, Sarah LR, István Pelczer. Beyond blood sugar: the potential of NMR-based metabonomics for type 2 human diabetes, and the horse as a possible model.Anal Bioanal Chem. 2007; 387:533–537.
  26. Ralston SL.Factors affecting tests of glucose and insulin metabolism in horses. In: Reed SR, W Bayley, Sellon D eds. Equine internal medicine. Saunders, StLouis. 2004;1600-1605.
  27. Ville-Petteri M, Pasi S, Carol F, et al. Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum.Magn Reson Mater Phy.2006;19:281-296.
  28. Wang CH, Zhu YF Zhou HL et al. Integrated analysis of serum untargeted metabolomics and targeted bile acid metabolomics for identification of diagnostic biomarkers for colorectal cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2023 Mar 20;43(3):443–453.
  29. Liu WS, Ma JL, Zhang JX, et al. Identification and validation of serum metabolite biomarkers for endometrial cancer diagnosis. EMBO Molecular Medicine. 2024; 16: 988-1003.
  30. Hu ZP. Opportunities and challenges of using tumor metabolomics for early tumor diagnosis. Journal of Pharmacy. 2024;59(3):689‑702.
  31. Bernhardt VG, Bernhardt KL, Pinto JRT, et al. Metabolomics in cancer detection: A review of techniques, biomarkers, and clinical utility. Biomedicine (Taipei). 2025;15(3):1–23.
  32. Yang J, Xu GW, Zhen YF, et al. Diagnosis of liver cancer using HPLC-based metabonomics avoiding false-positive result from hepatitis and hepatocirrhosis diseases.Journal of Chromatography B. 2004;813(1-2):59-65.
  33. Xu GW, Liebich H. Normal and modified nucleosides in urine as potential tumor markers analyzed by micellar electrokinetic capillary chromatography and high performance liquid chromatography.Am Clin Lab.2001;20(1):22-32.
  34. Shen P,Kang YF,Cheng YY.Methods for discovering metabolome pattern characteristics of breast cancer and HPLC/MS/MS analysis. Journal of Chemistry of Colleges and Universities.2005;26(10):1798-1802.
  35. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics.CA Cancer J Clin. 2001;51:15-36.
  36. Odunsi K, Wollman RM, Ambrosone CB, et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.Int J Cancer.2005;113(5):782-788.
  37. Liu TQ, Zhong XY. Application of metabolomics in neonatal clinical practice. Zhongguo Dang Dai Er Ke Za Zhi. 2019;21(9):942-948.
  38. Brindle JT ,Antti H , Holmes E, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-1-NMR-based metabonomics.Nat Med. 2002;8(12):1439-1444.
  39. Kazuki A, Misako I, Takao H. Investigations into Biochemical Changes of Genetic Hypertensive Rats Using 1H Nuclear Magnetic Resonance-Based Metabonomics.Hypertens Res. 2005;28(5):425-430.
  40. Serkova N, Fuller TF, Klawitter J, et al. 1H-NMR-based metabolic signatures of mild and severe ischemia-reperfusion injury in rat kidney transplants.Kidney Int. 2005; 67:1142–1151.
  41. David SW. Metabolomics in monitoring kidney transplants.Current Opinion in Nephrology and Hypertension.2006;15:637–642.
  42. Natalie JS, Zhang Y, et al. Early Detection of Graft Failure Using the Blood Metabolic Profile of a Liver Recipient.Transplantation. 2007;4(83):517-521.
  43. Olie SE, Staal SL, Ter Horst L, et al. Diagnostic accuracy of inflammatory markers in adults with suspected central nervous system infections. J Infect. 2024;88(3):106117.
  44. Muireann Coen, Matthew O’Sullivan, William A.Bubb, et al. Proton Nuclear Magnetic Resonance–Based Metabonomics for Rapid Diagnosis of Meningitis and Ventriculitis. Clinical Infectious Diseases. 2005;41:1582–1590.
  45. Rasmussen NF, Green A, Allin KH, et al. Clinical procedures used to diagnose inflammatory bowel disease: real-world evidence from a Danish nationwide population-based study. BMJ Open Gastroenterol. 2022;9(1):e000958.
  46. Julian RM, Elaine H, Fatima K, et al. Rapid and Noninvasive Metabonomic Characterization of Inflammatory Bowel Disease.Journal of Proteome Research. 2007;6:546-551.
  47. Lista S, González-Domínguez R, López-Ortiz S, et al. Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives. Ageing Res Rev. Author manuscript. 2023;89:101987.
  48. Zhao L, Wang C, Peng SJ, et al. Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke. Transl Med. 2022;20(1):459.
  49. Huang W, Hong X, Huang C, et al. Precision diagnosis model for treatment-resistant depression integrating serum metabolomics and clinical risk factors. Front Psychiatry. 2026; 17:1826019.
  50. Shih PB. Metabolomics Biomarkers for Precision Psychiatry. Adv Exp Med Biol. Author manuscript. 2019;1161:101-113.
  51. Fu Z, Xu X. Lysosomal checkpoints in renal autoimmunity: from antigen processing to metabolic-immune crosstalk. Front Immunol. 2026;17:1830023.
  52. Heckscher S, Ihlo NA, Schueler J, et al, Metabolomic profiling of renal cyst fluid in advanced ADPKD: insights from dialysis and transplantation cohorts. Metabolomics. 2025;21(4):90.
  53. Budnick I, Argabright A, Anderson CC, et al. Plasma metabolomics analysis in murine prerenal azotemia reveals changes in energy substrates, amino acid metabolism, and uremic toxins. Am J Physiol Renal Physiol. 2026;330(6):F683-F701.
  54. Schlosser P, Scherer N, Grundner-Culemann F. Genetic studies of paired metabolomes reveal enzymatic and transport processes at the interface of plasma and urine. Nat Genet. 2023; 55(6):995-1008.
  55. Shih T, Hodeify R, Kaur J,et al. Machine Learning-Driven Metabolomic Biomarker Discovery in Glioblastoma: Advances, Challenges, and Future Directions.Int J Mol Sci. 2026;27(9):3842.
  56. Ding L, Zhang M, Fan B, et al. Metabolomics reveals key biomarkers for ischemic stroke: a systematic review of emerging evidence. Front Neurol. 2025;16:1630390.